Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Miles Hamberg

Physician Assistant Westminster, CO Physician Assistant

NPI 1275266629 CMS profile 11403585

500 W 144Th Ave Ste 220, Westminster, CO 80023

Open in the dashboard

General payments

$5,866

173 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Miles Hamberg of Westminster, CO is reported in the CMS Open Payments database as having received $5,866 across 173 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,917 67
2024 General $1,439 53
2023 General $1,140 39
2022 General $371 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Miles Hamberg
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Miles Hamberg were reported at $2,917. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Miles Hamberg Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $371 $155 $48–$522 $149
2023 $1,140 $167 $52–$557 $160
2024 $1,439 $178 $55–$600 $164
2025 $2,917 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $1,581 10 payments
  2. Sumitomo Pharma America, Inc. $769 33 payments
  3. ConvaTec Inc. $372 17 payments
  4. Ferring Pharmaceuticals Inc. $319 8 payments
  5. Janssen Biotech, Inc. $304 10 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $289 11 payments
  7. AbbVie, Inc. $260 16 payments
  8. Astellas Pharma US Inc $249 6 payments
  9. Dendreon Pharmaceuticals LLC $227 5 payments
  10. Pfizer Inc. $185 9 payments
  11. Other $1,311 48 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,563 169 payments
  2. Travel and Lodging $1,139 2 payments
  3. Education $165 2 payments
Products named General payments · program years 2022–2025
  1. Axonics $1,562 10 payments
  2. ORGOVYX Hormone Therapy $420 20 payments
  3. ERLEADA $386 11 payments
  4. GENTLECATH $340 15 payments
  5. ADSTILADRIN $319 8 payments
  6. Nubeqa $289 11 payments
  7. Xofigo $258 10 payments
  8. PROVENGE $227 5 payments
  9. ORGOVYX Prostate Cancer $220 8 payments
  10. XTANDI $212 10 payments
  11. Other $2,369 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,214

Median for Physician Assistant: 241

Drug cost

$709,305

Median for Physician Assistant: $4,110

Branded share of claims

40.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 23 $382,087
Myrbetriq Mirabegron Brand 162 $159,959
Orgovyx Relugolix Brand 32 $85,070
Gemtesa Vibegron Brand 60 $55,973
Methenamine Hippurate Generic 64 $6,776
Tamsulosin Hcl Generic 352 $5,146
Abiraterone Acetate Generic 15 $2,437
Estradiol Generic 28 $1,974
Solifenacin Succinate Generic 40 $1,492
Potassium Citrate Er Potassium Citrate Brand 15 $1,476

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$101,050

Of which drugs: $31,149

Medicare patients

384

Average age 74

Services billed

4,619

104 women, 280 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 41%
Ischemic heart disease 32%
Diabetes 30%
Chronic kidney disease 30%
Cancer 28%
Depression 22%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 20 141 $19,802

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $260
$260 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $173
  • PFIZER INC. $27
$199 32 —
LUPRON DEPOT
  • AbbVie, Inc. $93
$93 — 141
ERLEADA
  • Janssen Biotech, Inc. $60
$60 — —
BOTOX
  • AbbVie, Inc. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

173 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record